Author

Jinkun Zhang 1

1 Arena Pharmaceuticals,San Diego,United States

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF A SELECTIVE, ORAL SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATOR, ETRASIMOD (APD334), IN MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS FROM THE OASIS STUDY

William Sandborn, Laurent Peyrin-Biroulet, Luba Trokan, Jinkun Zhang, Tanja Kühbacher, Michael Chiorean, Scott D. Lee, Severine Vermeire, Bruce Yacyshyn, Snehal U. Naik, Preston Klassen, Julian Panés

EARLY AND DURABLE SYMPTOM CONTROL IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH ETRASIMOD (APD334) IN THE RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 OASIS TRIAL AND OPEN LABEL EXTENSION

Michael Chiorean, Severine Vermeire, Julian Panés, Laurent Peyrin-Biroulet, Jinkun Zhang, Bruce E. Sands, Chris Cabell, Snehal U. Naik, William Sandborn

Long-term efficacy and safety of etrasimod for ulcerative colitis: results from the open-label extension of the OASIS study

Severine Vermeire, Julian Panés, Michael Chiorean, Laurent Peyrin-Biroulet, Jinkun Zhang, Bruce E. Sands, Krisztina Lazin, Chris Cabell, Snehal U. Naik, Preston Klassen, William Sandborn

PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ETRASIMOD (APD334) IN SUBJECTS WITH MILD, MODERATE, OR SEVERE HEPATIC IMPAIRMENT: A SINGLE-DOSE, OPEN-LABEL, PARALLEL-GROUP STUDY

Caroline A. Lee, Yong Tang, Cassandra Schroeder, Jinkun Zhang, Thai Nguyen-Cleary, Susan Mullin, Michael Ma, Naomi Lyon, John S. Grundy

Item 1 - 4 / 4
1